Class II · Moderate riskTerminated Initiated Mar 15, 2021 (5 years ago)
Belsomra (suvorexant) tablets 10 mg Each tablet contains 10 mg suvorexant. This package…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
What was recalled
Belsomra (suvorexant) tablets 10 mg Each tablet contains 10 mg suvorexant. This package contains 30 Tablets in 3 Blister Cards. Each Blister Card contains 10 Tablets Rx only NDC 00006-0033-30 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA
Recalling firm
Cardinal Health Inc.
NDC code
00006-0033-30
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0522-2021
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Reason Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the…